Aptevo Therapeutics Inc Stock

$3.03

4.48% today

Nasdaq, Jul 08, 07:16 pm CET

ISIN

US03835L1089

Symbol

APVO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Aptevo Therapeutics Inc Stock price

$2.90

-305,084.30 100.00% 5Y

Nasdaq, Closing price Mon, Jul 07 2025

-0.14 4.61%

ISIN

US03835L1089

Symbol

APVO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$9.4m

Enterprise Value

$7.2m

Net debt

positive

Cash

$2.1m

Shares outstanding

70.0k

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

negative

Financial Health

Equity Ratio

30.5%

Return on Equity

-504.7%

ROCE

-816.8%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-23.8m | -

EBIT

$-24.1m | $-23.4m

Net Income

$-23.7m | $-22.6m

Free Cash Flow

$-23.7m

EPS

$-325.0

FCF per Share

$-338.7

Short interest

1.5%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

Get Started for Free Today

Aptevo Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Aptevo Therapeutics Inc forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Aptevo Therapeutics Inc forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Aptevo Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	9.84 9.84	14% 14% -
- Research and Development Expense	14 14	15% 15% -
EBITDA	-24 -24	14% 14% -
- Depreciation and Amortization	0.31 0.31	38% 38% -
EBIT (Operating Income) EBIT	-24 -24	14% 14% -
Net Profit	-24 -24	12% 12% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Aptevo Therapeutics Inc Stock News

Neutral

Accesswire

●

18 days ago

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 2,465,000 shares of its common stock or pre-funded warrant...

Neutral

Accesswire

●

18 days ago

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumors New candidate APVO455 targets Nectin-4+ cancers, joins mipletamig (AML) and APVO442 (prostate) in Aptevo's tumor-directed CD3 suite SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (Nasdaq:APVO), ...

Positive

Market Watch

●

20 days ago

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Aptevo Therapeutics shares bounced back from Tuesday's 52-week low, more than doubling Wednesday after the company reported favorable results for its lead drug candidate in an acute myeloid leukemia study.

More Aptevo Therapeutics Inc News

Company Profile

Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Head office	United States
CEO	Marvin White
Employees	37
Founded	2016
Website	aptevotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now